Leerink Partnrs Issues Optimistic Forecast for ROIV Earnings

Roivant Sciences Ltd. (NASDAQ:ROIV) – Investment analysts at Leerink Partnrs raised their Q2 2026 earnings estimates for Roivant Sciences in a research report issued on Wednesday, September 17th. Leerink Partnrs analyst D. Risinger now expects that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($0.32). The consensus estimate for Roivant Sciences’ current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Roivant Sciences’ FY2027 earnings at ($1.27) EPS.

A number of other equities research analysts have also recently commented on ROIV. Leerink Partners increased their price target on shares of Roivant Sciences from $18.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday. The Goldman Sachs Group increased their price target on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a “buy” rating in a report on Thursday. Citigroup initiated coverage on shares of Roivant Sciences in a report on Tuesday, September 2nd. They set a “buy” rating and a $16.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Guggenheim increased their price objective on shares of Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $19.94.

Roivant Sciences Stock Down 0.3%

NASDAQ:ROIV opened at $15.04 on Monday. The company’s 50 day moving average price is $12.22 and its 200-day moving average price is $11.29. Roivant Sciences has a 52 week low of $8.73 and a 52 week high of $16.05. The stock has a market cap of $10.27 billion, a price-to-earnings ratio of -21.49 and a beta of 1.15.

Institutional Trading of Roivant Sciences

Several institutional investors and hedge funds have recently modified their holdings of the company. Valeo Financial Advisors LLC bought a new stake in shares of Roivant Sciences during the 2nd quarter valued at $1,145,000. Osaic Holdings Inc. grew its stake in shares of Roivant Sciences by 204.2% in the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock worth $65,000 after buying an additional 3,882 shares in the last quarter. Orion Porfolio Solutions LLC purchased a new position in shares of Roivant Sciences in the 2nd quarter worth $117,000. State of Wyoming bought a new stake in shares of Roivant Sciences in the 2nd quarter worth about $159,000. Finally, Headlands Technologies LLC lifted its holdings in shares of Roivant Sciences by 11,882.5% in the 2nd quarter. Headlands Technologies LLC now owns 162,003 shares of the company’s stock worth $1,826,000 after acquiring an additional 160,651 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Eric Venker sold 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $11.72, for a total transaction of $1,172,000.00. Following the sale, the chief executive officer directly owned 1,653,585 shares in the company, valued at $19,380,016.20. This trade represents a 5.70% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Matthew Gline acquired 3,315 shares of the firm’s stock in a transaction dated Thursday, September 18th. The shares were purchased at an average price of $15.07 per share, for a total transaction of $49,957.05. Following the completion of the transaction, the chief executive officer directly owned 17,287,081 shares in the company, valued at approximately $260,516,310.67. This trade represents a 0.02% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 1,975,749 shares of company stock worth $24,780,210 in the last three months. Company insiders own 10.80% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.